COMPANY RESEARCHInnovent Biologics, Inc.
Innovent Biologics is a China-based biopharmaceutical company involved in research, development, manufacturing and commercialization of innovative medicines. Its technology base includes therapeutic antibodies and other protein-based medicines, with research across cancer, autoimmune diseases and cardiometabolic disorders. The company works with internal scientific teams and external partners to develop therapies and expand access to treatment. Innovent maintains an official corporate website and investor communications for its Hong Kong-listed issuer. Its principal approach brings biologic discovery together with clinical and commercial development.
Company at a glance
Corporate information
- Company entity
- Innovent Biologics, Inc.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://en.innoventbio.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
HKEX: 01801
antibodies · protein therapeutics
oncology · autoimmune disease · cardiovascular and metabolic disease · ophthalmology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Innovent Biologics is a China-based biopharmaceutical company involved in research, development, manufacturing and commercialization of innovative medicines. Its technology base includes therapeutic antibodies and other protein-based medicines, with research across cancer, autoimmune diseases and cardiometabolic disorders. The company works with internal scientific teams and external partners to develop therapies and expand access to treatment. Innovent maintains an official corporate website and investor communications for its Hong Kong-listed issuer. Its principal approach brings biologic discovery together with clinical and commercial development.
Business, technology & evidence
- SecuritiesHKEX: 01801
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Innovent Biologics, Inc. ↗Innovent Biologics, Inc. ·
- Official issuer and R&D disclosure · Innovent Biologics, Inc. ↗Innovent Biologics, Inc. ·
- Official issuer and R&D disclosure · Innovent Biologics, Inc. ↗Innovent Biologics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.